Author: Nichols Martin|| Date Published: July 31, 2020
Pharmaceutical company GlaxoSmithKline has been awarded a $342M contract by the U.S. Army to obtain COVID-19 vaccines in mass quantities from multiple vendors.
The service branch obligated the full contract amount at the time of award to support coronavirus response efforts at military sites within and outside the continental U.S., the Department of Defense said Thursday.
Army Contracting Command received one bid for the procurement.
Contract work will take place at Research Triangle Park in North Carolina through Feb. 28, 2021.
PDW is acquiring Vanteon to expand tactical communications capabilities The acquisition will bring expertise in RF systems, software-defined radios and…
CISA is planning a $100 million cyber operations contract supporting threat-hunting missions The requirement will provide technical and operational support…
Valiant Solutions is expanding its cybersecurity portfolio through the acquisition of BreakPoint Labs The acquisition will bring operational technology security,…
